Company / Cash & Equivalents
Alkermes plc Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$388.6M
FY2025
5-year range
$291.1M / $457.5M
FY2021-FY2025
Trend
+33.5%
vs FY2024
Sector context
#49 of 207
Health Care
What the data says
Alkermes plc's cash & equivalents of $389M is higher than 76% of companies in the Health Care sector (FY2025). Cash & Equivalents has fluctuated over the past 10 years, ranging from $186M in FY2016 to $457M in FY2023.
Based on SEC 10-K filings.
$389M in FY2025 with a 5-year CAGR of +7.3%. Top quartile in the Health Care sector.
Declined from $457M to $389M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +9.9%
- 5-Year CAGR
- +7.3%
- 10-Year CAGR
- -
Sector benchmark
-42.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +7.3%, indicating consistent growth.
- In FY2025, cash & equivalents increased 33.5% year-over-year.
- Ranks #49 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2023.
Company context
Key Data Points
- Strong profit margin: 22.3%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $388.6M | +33.5% |
| FY2024 | $291.1M | -36.4% |
| FY2023 | $457.5M | +56.4% |
| FY2022 | $292.5M | -13.4% |
| FY2021 | $337.5M | +23.7% |
| FY2020 | $273.0M | +34.0% |
| FY2019 | $203.8M | -23.6% |
| FY2018 | $266.8M | +39.4% |
| FY2017 | $191.3M | +2.6% |
| FY2016 | $186.4M | +11.2% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026